Stock events for Inhibrx Biosciences, Inc. (INBX)
In the past six months, Inhibrx Biosciences, Inc. stock has experienced a substantial increase of 512.94% between February 27, 2025, and February 26, 2026. In October 2025, positive topline results were announced from the ChonDRAgon study for ozekibart (INBRX-109). In November 2025, the company reported its third-quarter 2025 financial results. In December 2025, updates were provided on the INBRX-106 program and ozekibart expansion cohorts. Also in December 2025, Citizens reiterated a "Market Perform" rating, citing concerns about limited data disclosures and a lack of management communication.
Demand Seasonality affecting Inhibrx Biosciences, Inc.’s stock price
There is no specific information available regarding demand seasonality for Inhibrx Biosciences, Inc.'s products or services, as it is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates that are not yet commercially available.
Overview of Inhibrx Biosciences, Inc.’s business
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutics for life-threatening conditions. The company operates in the Biotechnology and Medical Research industry, utilizing proprietary modular protein engineering platforms. Its clinical pipeline includes Ozekibart (INBRX-109), a tetravalent therapeutic candidate targeting DR5, being investigated for chondrosarcoma, metastatic colorectal cancer, and Ewing sarcoma. INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4, is being developed for various metastatic solid tumors. INBRX-101, a protein therapeutic for alpha-1 antitrypsin deficiency, was acquired by Sanofi in May 2024.
INBX’s Geographic footprint
Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. Its primary operations and clinical trials are conducted within the United States.
INBX Corporate Image Assessment
Inhibrx Biosciences' brand reputation has been influenced by positive clinical advancements and analyst concerns. The positive topline results from the ChonDRAgon study for ozekibart (INBRX-109) enhanced the company's scientific and clinical reputation. However, an analyst from Citizens reiterated a "Market Perform" rating, expressing concerns about limited data disclosures and lack of management communication.
Ownership
Inhibrx Biosciences, Inc. has a mixed ownership structure, with approximately 82.46% of the stock held by institutions and 17.09% held by insiders. Major institutional owners include Perceptive Advisors Llc, Viking Global Investors Lp, Morgan Stanley, Sanofi, HighTower Advisors, LLC, BlackRock, Inc., Vanguard Group Inc, Sofinnova Investments, Inc., Capital Research Global Investors and State Street Corp.
